Fujifilm invests $112m on two fronts with new site and expansion

By Ben Hargreaves contact

- Last updated on GMT

Rendering of facility in Wisconsin. (Image: Fujifilm Cellular Dynamics)
Rendering of facility in Wisconsin. (Image: Fujifilm Cellular Dynamics)

Related tags: Fujifilm diosynth biotechnologies, Fujifilm Cellular Dynamics, Fujifilm

Fujifilm has launched an upgrade to its subsidiaries manufacturing capabilities, by increasing capacity by 50% at an existing facility and building an entirely new site for cell technology.

The two separate investments involve building a $21m (€17.4m) site, which will be added to Fujifilm Cellular Dynamics (FCDI)’s network, and using ¥10bn ($91.9m) to expand operations at Fujifilm Diosynth Biotechnologies (FDB).

FCDI’s site will be based in Madison, Wisconsin, and focus on manufacturing human induced pluripotent stem (iPS) cell technologies. The site is expected to begin operations in March 2020.

Seimi Satake, CEO of FCDI, told us that the facility will have a dual focus: “FCDI will establish the cGMP-compliant facility to enhance and accelerate production of iPS cells for both its internal cell therapeutics pipeline, as well as serving as a contract development and manufacturing organisation (CDMO).”

According to Satake, FCDI is aiming to develop regenerative treatments using iPS cells, for age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, heart diseases, and cancer.

Satake stated that new hires would be brought in as needed by the progression of the company’s regenerative medicines portfolio and alongside the expansion of the CDMO side of the business.

Further expansion

FDB will use its investment to expand its North Carolina-based operations – $91.9m of funding will be used to add 2,000L of single use cell culture manufacturing trains, cell culture purification suites, and microbial recovery suites.

This will see the site increase its cell culture manufacturing capacity by approximately 25% and its microbial capacity by approximately 50%. The company noted in a statement that the expansion has been made in relation to “growing customer demand.”

The upgraded facilities are expected to complete in early 2020.

Related news

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Related suppliers

Follow us

Products

View more

Webinars